UNSPSC 51131830: Aprotinin/Fibrinogen+Calcium chloride/Thrombin

Aprotinin, calcium chloride, fibrinogen, and thrombin combination is used to help control bleeding during surgery when other procedures to close a wound or incision.

UNSPSC 51131830 Aprotinin/Fibrinogen+Calcium chloride/Thrombin, Commodity tier, shows minimal recent state and local procurement activity aligned directly with this hemostatic pharmaceutical code. The source block contains no active solicitations naming these specific products or their pharmaceutical equivalents as primary deliverables. One record tagged to this code (Seminole County's Naloxone and Safe Drug Deactivation Systems procurement, ITQ #IFB60459723LAS, posted June 30, 2026, due July 26, 2023) addresses opioid reversal and drug deactivation rather than surgical hemostatic agents, representing a substantial categorical mismatch. A second record (City of Tucson Fire Department BLS/ALS Pharmaceuticals RFP #260217, posted June 24, 2026, due June 24, 2026) encompasses broad emergency medical services pharmaceuticals and supplies but does not specifically name aprotinin, fibrinogen, calcium chloride, or thrombin formulations in its disclosed scope. The remaining opportunities in the source block address vendor forums, networking events, drug standards procurement for forensic analysis, behavioral health services, employee clinic services, and cooperative purchasing arrangements—none directly soliciting the specialized hemostatic products this code represents.

State and local governments purchasing under this code, when active, typically include hospital systems, trauma centers, surgery centers, and blood banks seeking pharmaceutical hemostasis agents for perioperative and acute bleeding control. Recent activity does not support characterization of issuing-body concentration, geographic spread, or current market demand. No representative recent opportunities targeting aprotinin, fibrinogen, calcium chloride, or thrombin products appear in the available records, suggesting either very limited procurement velocity under this code or systematic tagging misalignment in the source dataset. Firms pursuing this commodity should monitor activity directly through state health department and hospital procurement channels rather than rely on broad UNSPSC-tagged notices to surface hemostatic pharmaceutical opportunities.